These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27133664)

  • 1. A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity.
    Lomenick JP; Buchowski MS; Shoemaker AH
    Obesity (Silver Spring); 2016 Jun; 24(6):1222-5. PubMed ID: 27133664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
    Mack CM; Moore CX; Jodka CM; Bhavsar S; Wilson JK; Hoyt JA; Roan JL; Vu C; Laugero KD; Parkes DG; Young AA
    Int J Obes (Lond); 2006 Sep; 30(9):1332-40. PubMed ID: 16534527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome.
    Sze L; Purtell L; Jenkins A; Loughnan G; Smith E; Herzog H; Sainsbury A; Steinbeck K; Campbell LV; Viardot A
    J Clin Endocrinol Metab; 2011 Aug; 96(8):E1314-9. PubMed ID: 21632815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity.
    van Schaik J; Begijn DGA; van Iersel L; Vergeer Y; Hoving EW; Peeters B; van Santen HM
    Obes Facts; 2020; 13(4):361-370. PubMed ID: 32781455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
    Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 agonist exendin-4 leads to reduction of weight and caloric intake in a rat model of hypothalamic obesity.
    Elfers CT; Simmons JH; Roth CL
    Horm Res Paediatr; 2012; 78(1):47-53. PubMed ID: 22831885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes.
    Tokuda M; Katsuno T; Ochi F; Miyakoshi K; Kusunoki Y; Murai K; Miuchi M; Hamaguchi T; Miyagawa J; Namba M
    Endocr J; 2014; 61(4):365-72. PubMed ID: 24452017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
    Leinung MC; Grasso P
    Regul Pept; 2012 Nov; 179(1-3):33-8. PubMed ID: 22960403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA; Kane MP; Busch RS
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
    Buse JB; Drucker DJ; Taylor KL; Kim T; Walsh B; Hu H; Wilhelm K; Trautmann M; Shen LZ; Porter LE;
    Diabetes Care; 2010 Jun; 33(6):1255-61. PubMed ID: 20215461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
    Salehi P; Hsu I; Azen CG; Mittelman SD; Geffner ME; Jeandron D
    Pediatr Obes; 2017 Jun; 12(3):221-228. PubMed ID: 27071367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide as a novel weight loss modality in patients without diabetes.
    Moreno JL; Willett KC; Desilets AR
    Ann Pharmacother; 2012 Dec; 46(12):1700-6. PubMed ID: 23191935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study).
    Xu W; Bi Y; Sun Z; Li J; Guo L; Yang T; Wu G; Shi L; Feng Z; Qiu L; Li Q; Guo X; Luo Z; Lu J; Shan Z; Yang W; Ji Q; Yan L; Li H; Yu X; Li S; Zhou Z; Lv X; Liang Z; Lin S; Zeng L; Yan J; Ji L; Weng J
    J Intern Med; 2015 Jan; 277(1):137-50. PubMed ID: 25039675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.
    Basolo A; Burkholder J; Osgood K; Graham A; Bundrick S; Frankl J; Piaggi P; Thearle MS; Krakoff J
    Metabolism; 2018 Aug; 85():116-125. PubMed ID: 29596853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.
    Su N; Li Y; Xu T; Li L; Kwong JS; Du H; Ren K; Li Q; Li J; Sun X; Li S; Tian H
    Int J Cardiol; 2016 Sep; 219():293-300. PubMed ID: 27343423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity.
    Nathan BM; Rudser KD; Abuzzahab MJ; Fox CK; Coombes BJ; Bomberg EM; Kelly AS
    Clin Obes; 2016 Feb; 6(1):73-8. PubMed ID: 26683756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist.
    Shoemaker AH; Silver HJ; Buchowski M; Slaughter JC; Yanovski JA; Elfers C; Roth CL; Abuzzahab MJ
    Int J Obes (Lond); 2022 Mar; 46(3):623-629. PubMed ID: 34975146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.